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Abstract 
 
Background 
Skin conditions may have a major impact on the psychological well-being of 
patients, ranging from depression to anxiety. The Dermatology Life Quality 
Index (DLQI) is the most commonly used quality of life tool in dermatology, 
though it has yet to be correlated with psychiatric measures used in clinical 
therapeutic trials. 
 
Objectives 
We conducted a systematic review to determine whether there is any 
correlation between the DLQI and psychiatric measure scores, potentially 
allowing the DLQI to be used as a surrogate measure for depression or 
psychiatric screening. 
 
Methods 
Six databases were searched using the keywords: ‘DLQI’, ‘Dermatology Life 
Quality Index’, ‘Psych*’, ‘depression’, ‘anxiety’, ‘stress’ and ‘trial*’. All randomised 
trials where full DLQI and psychiatric scores were provided were included. 
PRISMA guidelines were followed. 
 
Results 
462 records were screened but only seven met inclusion criteria. Hospital 
Anxiety and Depression Scale (HADS) was the most commonly used 
psychiatric measure; the ‘depression’ component score changes correlated 
strongly with the DLQI (r=0.715). 
 
Conclusions 
There needs to be guidance on psychiatric measurement and reporting in 
clinical trials. Though the DLQI correlated well with the ‘depression’ domain of 
the HADS scale, interviews and screening for depression are still vital for full 
assessment of patient psychological well-being as well as for fully 
understanding the wider impact of skin disease on patients 
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Introduction 
 
Skin conditions may have significant implications on a patient’s quality of life 
(QoL) affecting various aspects of their day-to-day living1. This includes 
routine activities, household chores, social interactions and relationships. 
There is a well-documented impact on psychological well-being, often 
manifesting in psychiatric problems ranging from depression to anxiety2. 
Several studies have examined the relationship between psychiatric morbidity 
and skin diseases3-7. Psoriasis is associated with psychological disorders with 
sexual and sleep complaints being the most prevalent3.  Anxiety and 
depression are strongly correlated in conditions such as alopecia areata4, 
vitiligo5, rosacea6 and hirsutism7. 
 
The Dermatology Life Quality Index8 (DLQI, score range 0-30) has been used 
in many skin conditions and across a wide range of disease severities9,10. It 
has high patient acceptability11, short completion time, and extensive 
validation9, resulting in its widespread use in clinical settings as well as clinical 
therapeutic research trials globally12. Furthermore, the psychosocial aspects 
captured by the DLQI are well documented10. Despite this, the DLQI has yet 
to be compared and correlated with other psychiatric morbidity measures in 
randomized controlled trials. 
 
We aimed to conduct a systematic review to identify the different validated 
psychiatric measures that have been utilized in conjunction with the DLQI in 
randomized controlled trials (RCTs), and whether there is any correlation 
between the scores that would potentially allow the DLQI to be used as a 
surrogate measure for depression or psychiatric screening. 
 
Materials and Methods 
 
Data sources 
 
Six computerized bibliographical databases were searched up to 19 May 
2016:  
OVID MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, 
EMBASE, WEB OF SCIENCE Core Collection, SCOPUS and PsycInfo. The 
search was not restricted by language and was conducted using PRISMA 
guidelines (Prospero registration no: XXX).  
 
Keywords used were: ‘DLQI’, ‘Dermatology Life Quality Index’, ‘Psych*’, 
‘depression’, ‘anxiety’, ‘stress’ and ‘trial*’. 
Search filters are given in the Supplementary Material. We ran supplementary 
searches and reviewed trial registers and grey literature. Reference lists of all 
included studies and of recent reviews were also assessed. Electronic 
publications in advance of print were also included. 
Selection criteria 
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We included all randomised controlled trials for any condition where the DLQI 
was used. This included cross-over trials and trials with open-label 
extensions, in all languages studying the adult population (aged 18 and over) 
of either sex and of any ethnicity. Only papers where the absolute scores or 
change in scores for the DLQI and for psychiatric measures were provided 
were included. 
 
Exclusion criteria 
 
The exclusion criteria for the systematic review were as follows: studies which 
included any patient less than 18 years of age, and articles where the change 
in scores could not be reliably calculated for the DLQI or any psychiatric 
morbidity scale (including graphical representation). Abstracts and posters 
where further data was not available upon contacting the author were also 
excluded.  
Outcome measures extracted 
Primary Outcome 
 
Data recorded included DLQI scores and which psychiatric morbidity scale 
was utilised. Scores for these measures were recorded at baseline, treatment 
and follow-up endpoints, as well as the change in these scores attributed to 
treatment. For studies with an open label extension, the data was only 
extracted for the period of the study while it was randomised and controlled.  
Secondary Outcomes 
 
Correlation between the sensitivity of the DLQI and psychiatric measures to 
change. 
Data extraction and synthesis 
 
Two reviewers (FA and NJ) extracted data independently from all eligible 
published studies, discussed any disagreements and, if necessary involved a 
third reviewer (Dr. Jui Vyas, Cardiff University) for resolution. We adapted a 
form, which included the Cochrane Risk of Bias tool, for recording data13 that 
included study design, details of administration, methodological quality and 
duration of treatment and follow-up. Article quality was quantitatively rated 
using the JADAD score14.  
 
Results 
 
Characteristics and attributes of the studies selected 
462 records were screened from the initial database search, of which only 
seven interventional RCTs met the inclusion criteria; six studies were for 
psoriasis and one for atopic dermatitis. One study, for which results were 
available, was identified by searching trial registries (Fig. 1). The data 
describes results from 5578 adult patients, with an average age of 45 years. 
Approximately 63.8% of the study population was male. The studies identified 
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by the systematic review and their extracted attributes are summarised in 
Table 1. 
 
The most common psychiatric tools used alongside the DLQI were: Beck 
Depression Inventory (BDI, 2 studies) and the Hospital Anxiety and 
Depression Scale (HADS, 5 studies). The BDI, published in 196122, is a 21-
item patient reported outcome measure (score range 0-63) and is commonly 
used in studies to assess the severity of depression. The inventory covers 
various aspects of mental health and depression as well as physical 
symptoms and relationships. The HADS scale was developed in 198323 as a 
screening tool and consists of 14 items (score range 0-21). The questions 
encapsulate two domains: anxiety (HADS-A) and depression (HADS-D), each 
containing seven questions with a four-level response system. Scores ranging 
from 0-7 are considered ‘normal’, 8-10 ‘borderline abnormal’ and 11-21 
‘abnormal’. 
 
DLQI and the psychiatric measures scores 
Mean scores at baseline ranged from 6.6-13.8 for the DLQI, 8.1-12.3 for the 
BDI, 5.0-6.6 for HADS-D and 6.8-8.3 for the HADS-A. At treatment endpoint, 
the scores ranged from 2.6-6.1 for the DLQI, 5.8-10.5 for BDI, 3.1-5.00 for 
HADS-D, 4.3-6.1 for HADS-A (Table 2) In five studies the DLQI was 
measured more frequently than the psychiatric scores throughout the study 
duration. However, only measurement scores for simultaneous assessment 
points of the two measures (i.e. DLQI, HADS or BDI) were examined.  
 
Relationships between the DLQI and psychiatric measures 
Change in score for these measures at treatment endpoint were recorded, or 
calculated where needed from the absolute data provided. As the HADS was 
the most commonly used tool (5 out of 7 studies), DLQI scores were 
correlated with this measure (Figure 2a and 2b). The HADS-Depression index 
was more closely correlated to the DLQI (R2=0.715) than the HADS-Anxiety 
index (R2=0.423). 
 
Relevance of accumulative change of scores for the DLQI and HAD Scale  
Table 2 demonstrates a mean HADS-D score across all studies of 5.76 
(‘normal’ according to the HADS-D scoring index23)  and a mean HADS-A 
score of 7.39 (‘borderline abnormal’). The expected DLQI score change per 
HADS-D point is 4.59 and 4.29 for the HADS-A. This suggests……… 
 
Discussion 
 
Depression and other psychiatric issues continue to be significant problems 
experienced by dermatology patients, potentially affecting treatment 
compliance, leading to premature treatment discontinuation and alteration of 
the disease course24. The implications extend beyond QoL for concerned 
individuals, with concurrent economic repercussions through lost productivity 
and sick leave25,26. Researchers therefore often administer QoL tools which 
encompass a psychological component alongside psychiatric measures 
where appropriate to gather holistic efficacy data, though these are 
predominantly cited as secondary outcomes. This systematic review 
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highlights the need for more frequent psychiatric assessment in RCTs, 
particularly where quality of life is measured; several studies had to be 
excluded from this review as a result. Full scores for psychiatric measures are 
not always provided, with researchers favouring clinical data instead. Though 
primary outcomes are centred around these clinical parameters, it is 
imperative psychiatric morbidity is not sidelined given its prevalence in this 
population2-7.  
 
Although the HADS is commonly used to assess symptoms of depression and 
anxiety, it is most appropriate as a screening tool with routine clinical 
psychiatric assessment considered as the primary diagnostic method27. The 
DLQI contains questions on various aspects of quality of life, including 
‘embarrassment’ and ‘self-consciousness’, but does not overtly record data on 
depression or anxiety8.  Nevertheless, the total DLQI score correlated well 
with score changes in the Depression component of the HADS, though not as 
well as with the Anxiety component (Figures 2a/b). It may be possible to 
consider depression and anxiety in patients using DLQI scores, especially in 
the absence of an appropriate psychiatric measure; a DLQI score change 
4.59 and 4.29 results in a point change for the HADS-D and HADS-A 
respectively. However, a significant limitation of this systematic review is that 
there was very little data in interventional trials where both DLQI and HADS 
values were provided, thereby necessitating further work on more expansive 
datasets for more accurate and refined correlation values. 
 
Several studies used inappropriate or non-validated scales to assess 
psychiatric morbidity, which led to their exclusion in this systematic review. 
The frequency at which this data was recorded compared to quality of life also 
varied across studies, despite majority of the identified studies belonging to 
the same intervention group. Generic and disease-specific QoL 
questionnaires may capture elements of depression and other mental health 
disorders, though these have not been validated as such for their primary 
purpose. Where psychiatric scores were provided, on occasion the authors 
omitted commenting on the results and therefore deducing worthwhile 
conclusions. We suggest guidelines to ensure routine and correct 
measurement of psychiatric symptoms using appropriate measures, alongside 
QoL assessment. The diverse and inconsistent nature of the data-reporting 
limits the potential to analyse and compare data between trials, whilst 
potentially missing cases of depression or other significant mental health 
issues. Almost all the studies identified in this review assessed psoriasis, a 
condition commonly linked with psychological distress28. In such cases, 
psychotherapy may be a significant adjuvant to traditional topical and 
systemic dermatological treatment, further highlighting the need for full and 
accurate reporting of psychological data. 
 
There are several limitations to this review. Though the focus was primarily on 
interventional studies, to capture more extensive correlation data, 
observational studies could also have been included. We only studied DLQI 
data given its widespread implementation12; further research correlating other 
QoL measures may highlight other patterns of data reporting. The mean 
baseline HADS-D score of 5.8 is rated ‘normal’ according to the screening 
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cut-off23, and 7.4 ‘borderline abnormal’ for the HADS-A. This highlights that 
mostly patients without, or with minimal, psychiatric morbidity were recruited, 
emphasising the limited availability of such data in trials. Perhaps if data with 
patients suffering with more significant psychiatric morbidity were available for 
RCTs, we might see higher score changes in the HAD scale, and 
subsequently more sensitive DLQI correlation values (Table 2). 
 
The results of this systematic review echo our recent calls for guidance on the 
reporting of QoL scores12; we extend these suggestions for psychiatric 
morbidity reporting. Patients often suffer with depression and suicidal 
ideation27 and if appropriate measures are not administered, these potentially-
serious symptoms may be missed, perhaps leading to avoidable detrimental 
consequences.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
 
 
 
 
 
 
 
References 
 
1. Finlay, AY, Ryan, TJ.: Disability and handicap in dermatology. Int J 
Dermatol. 1996; 35: 305–11. 
 
2. Jowett, S, Ryan, TJ.: Skin disease and handicap: an analysis of the impact 
of skin conditions. Soc Sci Med. 1985; 20:425–9. 
 
3. Ferreira, BI, Abreu, JL, Dos Reis, JP, Figueiredo, AM.: Psoriasis and 
Associated Psychiatric Disorders: A Systematic Review on Etiopathogenesis 
and Clinical Correlation. J Clin Aesthet Dermatol. 2016; 9(6):36. 
 
4. Karia, SB, De Sousa, A, Shah, N, Sonavane, S, Bharati, A.: Psychiatric 
morbidity and quality of life in skin diseases: A comparison of alopecia areata 
and psoriasis. Ind Psychiatry J. 2015; 24(2):125. 
 
5. Hedayat, K, Karbakhsh, M, Ghiasi, M, Goodarzi, A, Fakour, Y, Akbari, Z, 
Ghayoumi, A, Ghandi, N.: Quality of life in patients with vitiligo: a cross-
sectional study based on Vitiligo Quality of Life index (VitiQoL). Health Qual 
Life Outcomes. 2016; 14(1):1. 
 
6. Egeberg, A, Hansen, PR, Gislason, GH, Thyssen, JP.: Patients with 
Rosacea Have Increased Risk of Depression and Anxiety Disorders: A Danish 
Nationwide Cohort Study. Dermatology. 2016; 232(2):208-13. 
 
7. Ekbäck, MP, Lindberg, M, Benzein, E, Årestedt, K.: Health-related quality of 
life, depression and anxiety correlate with the degree of hirsutism. 
Dermatology. 2013; 227(3):278-84. 
 
8. Finlay, AY, Khan, G.: Dermatology Life Quality Index (DLQI)—a simple 
practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-
6. 
 
9. Mease, PJ, Menter, MA.: Quality-of-life issues in psoriasis and psoriatic 
arthritis: Outcome measures and therapies from a dermatological perspective. 
J Am Acad Dermatol. 2006; 54(4): 685-704 
 
10. Basra, MKA, Fenech, R, Gatt, RM, Salek, MS, Finlay, AY.: The 
Dermatology Life Quality Index 1994-2007: a comprehensive review of 
validation data and clinical results. Br J of Dermatol. 2008; 159:997-1035. 
 
11. Bronsard, V, Paul, C, Prey, S, Puzenat, E, Gourraud, PA, Aractingi, S, 
Aubin, F, Bagot, M, Cribier, B, Joly, P, Jullien, D.: What are the best outcome 
 9 
measures for assessing quality of life in plaque type psoriasis? A systematic 
review of the literature. JEADV. 2010; 24(2):17-22. 
 
12. Ali, FM, Cueva, AC, Vyas, J, Atwan, AA, Salek, MS, Finlay, AY, Piguet, 
V.: A systematic review of the use of quality of life instruments in randomised 
controlled trials of psoriasis. Br J Dermatol. 2016; 
https://dx.doi.org/10.1111/bjd.14788 
 
13. Higgins, JPT, Green, S.: Cochrane handbook for systematic reviews of 
interventions, Vol. 5: Wiley Online Library. 2008. 
 
14. Jadad, AR, Moore, RA, Carroll, D, Jenkinson, C, Reynolds, DJ, 
Gavaghan, DJ, McQuay, HJ.: Assessing the quality of reports of randomized 
clinical trials: is blinding necessary? Control Clin Trials. 1996; 17:1-12. 
 
15. Bostoen, J, Bracke, S, De Keyser, S, Lambert, J.: An educational programme for 
patients with psoriasis and atopic dermatitis: a prospective randomized controlled 
trial. Br J Dermatol. 2012; 167(5):1025-31. 
 
16. Bundy, C, Pinder, B, Bucci, S, Reeves, D, Griffiths, CE, Tarrier N.: A novel, web-
based, psychological intervention for people with psoriasis: the electronic Targeted 
Intervention for Psoriasis (eTIPs) study. Br J Dermatol. 2013; 169(2):329-36. 
 
17. Dauden, E, Griffiths, CE, Ortonne, JP, Kragballe, K, Molta, CT, Robertson D, 
Pedersen, R, Estojak, J, Boggs, R.: Improvements in patient-reported outcomes in 
moderate-to-severe psoriasis patients receiving continuous or paused etanercept 
treatment over 54 weeks: the CRYSTEL study. JEADV. 2009; 23(12):1374-82. 
 
18. Gelfand, JM, Kimball, AB, Mostow, EN, Chiou, CF, Patel, V, Xia, HA, Freundlich, 
B, Stevens, SR.: Patient-reported outcomes and health-care resource utilization in 
patients with psoriasis treated with etanercept: Continuous versus interrupted 
treatment. Value Health. 2008; 11(3):400-7. 
 
19. Gniadecki, R, Robertson, D, Molta, CT, Freundlich, B, Pedersen, R, Li W, Boggs, 
R, Zbrozek, AS.: Self-reported health outcomes in patients with psoriasis and 
psoriatic arthritis randomized to two etanercept regimens. JEADV. 2012; 
26(11):1436-43. 
 
20. Langley, RG, Feldman, SR, Han, C, Schenkel, B, Szapary, P, Hsu MC, Ortonne, 
JP, Gordon, KB, Kimball, AB.: Ustekinumab significantly improves symptoms of 
anxiety, depression, and skin-related quality of life in patients with moderate-to-
severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase 
III trial. J Am Acad Dermatol. 2010; 63(3):457-65. 
 
21. ClinicalTrials.gov. A Phase 3, Multi-Site, Randomized, Double-Blind, 
Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 
Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic 
Plaque Psoriasis. 2014 [Online] Available at: 
https://clinicaltrials.gov/ct2/show/study/NCT01309737?term=%22DLQI%22+A
 10 
ND+%22Depression%22&rank=3&sect=Xb0156_0a [Accessed 30 October 
2016] 
 
22. Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J.: An inventory 
for measuring depression. Arch Gen Psychiatry. 1961; 4(6): 561–71. 
 
23. Zigmond, AS, Snaith, RP.: The hospital anxiety and depression scale". 
Acta Psychiatr Scand. 1983; 67(6):361–370. 
 
24. Cvetkovski, RS, Zachariae, R, Jensen, H, Olsen, J, Johansen, JD, Agner, 
T.: Quality of life and depression in a population of occupational hand eczema 
patients. Contact Dermatitis. 2002; 54:106–111. 
 
25. Diepgen, TL.: Occupational skin-disease data in Europe. Int Arch Occup 
Environ Health. 2003; 76:331–338. 
 
26. Simon, GE, Barber, C, Birnbaum, HG.: Depression and work productivity: 
the comparative costs of treatment versus non treatment. J Occup 
EnvironMed. 2001; 43:2–9. 
 
27. Boehm, D, Schmid Ott, G, Finkeldey, F, John, SM, Dwinger, C, Werfel, T, 
Diepgen, TL, Breuer, K.: Anxiety, depression and impaired health related 
quality of life in patients with occupational hand eczema. Contact dermatitis. 
2012; 67(4):184-192. 
 
28. Russo, PA, Ilchef, R, Cooper, AJ.: Psychiatric morbidity in psoriasis: a 
review. Australas J Dermatol. 2004; 45(3):155-161. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11 
 
Figure 1 Flow diagram of article selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching (n = 462) 
- Medline / Medline in Progress / 
EMBASE / PsycINFO (n = 199) 
- Scopus (n=107) 
- Web of Science (n=156) 
Additional records identified through 
other sources 
- Trial registries (n=1) 
 
First screening (after duplicates removed) 
 (n=263) 
 
Full-text articles assessed for eligibility 
 (n=86) 
 
Records excluded on basis of title and abstract 
 (n=177) 
 
Full-text articles excluded with reasons 
 (n=72) 
 
Articles included in the systematic review  
 (n=7) 
 
Reasons for exclusion 
• Not a randomised controlled trial (n=34) 
• Psychiatric measures not used (n=38) 
• Full QoL/psychiatric data not provided 
(n=6) 
• Subanalysis (n=1) 
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Figures 2a & b 
 
a) Correlation between change in DLQI scores and HADS-D scores 
b) Correlation between change in DLQI scores and HADS-A scores 
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Table 1 Table of included studies, basic demographic information and psychiatric 
measures used 
 
 
 
Author, Year JADAD 
score 
Interventional 
study arm 
Condition Study 
duration 
(weeks) 
Average 
participant 
age 
Total no. of 
study 
participants 
Psychiatri
measure us
Bostoen 201215 4 Educational 
Programme 
Atopic 
dermatitis 
12 38.5 16 BDI 
Bundy 201316 2 eTIPS* Psoriasis 6 45.8 61 HADS 
Dauden 200917 1 Etanercept 
(Continuous) 
 
Psoriasis 
 
54 
44.8 352  
HADS 
Etanercept 
(Paused) 
45.2 359 
Gelfand 200818 1 Etanercept 
(Continuous) 
 
Psoriasis 
 
12 
45.8 1272  
BDI 
Etanercept 
(Interrupted) 
44.9 1274 
Gniadecki 201219 3 
Etanercept BIW†  Psoriasis 
 
12 
46.1 379  
HADS 
Etanercept QW†† 46.9 373 
Langley 201020 4 Ustekinumab 45 
mg 
 
Psoriasis 
 
52 
45.1 409  
HADS 
Ustekinumab 90 
mg 
46.6 411 
Trial No: 
NCT0130973721 
N/A CP-690,550  
5 mg 
 
Psoriasis 
 
52 
45.9 331  
HADS 
CP-690,550 10 
mg 
44.3 341 
 
* eTIPS, electronic Targeted Intervention for Psoriasis 
† BIW, twice weekly 
†† QW, once weekly 
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Table 2 Baseline scores and change in scores after treatment as reported in 
each study 
 
Author, 
Year 
Interventiona
l study arm 
Baseline 
score 
HADS-D  
Baseline 
score 
HADS-A 
Baseline 
score 
DLQI 
Change in 
score 
HADS-D 
Change in 
score 
HADS-A  
 
Change in 
score 
DLQI 
Expected 
DLQI score 
change for
1 HADS-D 
point 
Bundy 
201316 
eTIPS* 5.00 7.60 6.60 -.61 -.77 -2.46 4.03 
Dauden 
200917 
Etanercept 
(Continuous) 
5.70 7.21 12.80 -1.76 -1.99 -8.75 4.97 
Etanercept 
(Paused) 
6.20 7.67 13.80 -1.53 -1.84 -7.71 5.04 
Gniadecki 
201219 
Etanercept 
BIW† 
6.60 8.30 12.30 -1.60 -1.90 -7.90 4.94 
Etanercept 
QW†† 
6.40 8.00 12.30 -1.40 -1.70 -6.80 4.86 
Langley 
201020 
Ustekinumab 
45 mg 
 
4.90 
6.80 12.20 -1.70 -1.60 -9.30 5.47 
Ustekinumab 
90 mg 
5.40 6.90 12.60 -2.10 -1.60 -10.00 4.76 
Trial No: 
NCT01309
73721 
CP-690,550  
5 mg 
6.00 7.05 13.22 -2.38 -2.69 -8.18 3.44 
CP-690,550 
10 mg 
5.64 6.94 12.69 -2.50 -2.62 -9.43 3.77 
 
 
Mean 
(SD) 
 5.76 
(0.59) 
7.39 (0.53) 11.1 (2.16) -1.73 
(0.57) 
-1.86 
(0.57) 
-7.84 4.59 
Range 4.90 to 
6.60 
6.80 to 
8.30 
6.60 to 
13.80 
-2.50 to  
-0.61 
-2.69 to  
-0.77 
-10.00 to  
-2.46 
3.44 to 5.47
 
* eTIPS, electronic Targeted Intervention for Psoriasis 
† BIW, twice weekly 
†† QW, once weekly 
 
